I too thought 18% royalty is low also, but based on what I could find that is in-line with other deals.....so I used it. This likely explains why most of the big pharmas would rather buy they can still make a lot of money with less risk.

What I don't know and maybe someone more knowledgeable in the licensing field can explain is if this percentage increases based on revenue thresholds? Say 18% for first $500M, then 20% between $500M-$1B and 25% anything above $1B?....or what a reasonable rate and threshold limits would be?

This will move the needle a lot more especially as our 10.5% payout rates are likely structured similar but at much small levels sine they were inked much earlier in leronlimab's trial progress.